Bayer dropping bid to market higher-dose MS treatment Betaferon; takes charge

FRANKFURT, Germany - German drugmaker Bayer AG said Monday it will take a charge of about US$218.64 million from a decision to abandon plans to market a bigger dose of its multiple sclerosis treatment Betaferon....More